- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04518774
Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial
August 18, 2020 updated by: Beijing 302 Hospital
The Safety Assessment of Ex-Vivo Expanded Allogeneic γδT Cells in Hepatocellular Carcinoma Patients in Phase 1 Clinical Trial
This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of hepatocellular carcinoma patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study is a single-center, non-randomized, open label, no control, prospective clinical trial to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells from of a blood-related donor of Hepatocellular Carcinoma (HCC) Patients.
This study will include the following sequential phases: sign informed consent, γδT cell pre-culture, screening and registration to the trial, apheresis, γδT cell preparation, treatments and follow-ups.
Study Type
Interventional
Enrollment (Anticipated)
8
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100039
- Recruiting
- Beijing 302 Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100039
- Recruiting
- Beijing 302 Hospital of China
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Patient Inclusion Criteria:
- Patients should sign informed consent form voluntarily before the trail and comply with the requirements of this study.
- Age 18 years up to the age of 65 (≤65), gender unlimited.
- Hepatocellular Carcinoma diagnosed according to the 2018 edition of the EASL guidelines. Patients should accept liver biopsy voluntarily and histopathologically diagnosed with HCC.
- Interventional therapy (e.g. TACE), RFA or radiation therapy should be at least 2 weeks prior to γδT cell transfusion; surgical treatment should be at least 1 month prior to γδT cell transfusion. Patients can take the first- or second-line targeted drugs recommended by the guidelines, such as lenvatinib or sorafenib.
- Liver function: Child-Pugh class A/B (5-9)
- Eastern Cooperative Oncology Group (ECOG) Performance score≤2.
- Life expectancy of at least 1 year.
- Patients combined with HBV infection require antiviral treatment with nucleoside analogues; patients combined with HCV infection require direct-acting antiviral agent (DAA) treatment.
- Male and female patients of reproductive potential must agree to use birth control during the study and for at least 30 days post study.
Patient Exclusion Criteria:
- Patients combined with HAV, HEV, HIV or other infectious diseases.
- Acute infections, gastrointestinal bleeding, etc. occurred within 30 days before screening.
- Women who are pregnant (urine/blood pregnancy test positive) or lactating; patients with severe autoimmune diseases; patients with uncontrolled infectious diseases.
Major organs dysfunction:
- Peripheral blood: WBC<1.0×109/L, PLT <60×109/L, Hb <86g/L;
- Coagulation: INR>2.3, PT>18s;
- Liver function: ALB<28g/L, TBIL>51mmol/L, ALT/AST>5 times the upper limit of normal, CREA>1.5 times the upper limit of normal.
- Combined with other severe organic diseases or mental illnesses, including any uncontrolled clinically significant systematic diseases such as urinary, circulatory, respiratory, neurological, psychiatric, digestive, endocrine and immune diseases.
- Allergic constitution, history of allergies to blood products, known to be allergic to test substances.
- Immunosuppressive or systemic cytotoxic drugs may require within 6 months prior to screening or during the study; 6 months prior to screening accepted other cell therapies including NK, CIK, DC, CTL and stem cell therapy etc.; immunotherapy such as PD-1 and PD-L1 antibodies.
- Patients currently participating in other clinical trials who may violate this treatment plan and observations.
- Those who are unable or unwilling to provide informed consent or who are unable to comply with the research requirements.
- Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed: patients with any serious acute or chronic physical or mental illness, or laboratory abnormalities.
Donor Inclusion Criteria:
- Sign informed consent form.
- Age 18 years up to the age of 50 (≤50), gender unlimited.
- Relative to patients (unrestricted to blood relationship).
- Apheresis available.
- PLT≥100×109/L with normal APTT or PT.
Donor Exclusion Criteria:
- History of any severe clinical diseases or other severe organic diseases, including any history of clinically significant systematic diseases such as cardiovascular, urinary, circulatory, respiratory, neurological, psychiatric, digestive and endocrine diseases. History of high blood pressure or systolic pressure>140 mmHg, diastolic pressure>90 mmHg in screening stage. Any situation that investigators believe is clinically significant or with other severe diseases unsuitable of apheresis.
- Arterial thrombosis or venous thrombosis history 12 months prior to the trial or hemorrhagic tendency or history 2 months prior to the trial; oral administration of anticoagulation drugs (e. g. aspirin and warfarin).
- Active or history of autoimmune diseases including but not restricted to SLE, psoriasis, RA, IBD and HT. Apart from hypothyrosis which can be controlled by hormone replacement therapy, skin diseases without systemic therapy and celiac disease which is fully controlled.
- HIV-Ab, TP-Ab, HCV-Ab, HBsAg, HBeAg, HBeAb or HBcAb positive.
- Any symptom, sign or laboratory examination abnormality suggesting acute or subacute infection (e.g. fever, cough, urinary irritation, skin infectious wound).
- Female who are pregnant or cannot stop lactating.
- Those who cannot communicate with medical staff due to mental illness or language disabilities.
- Other unsuitable conditions that investigators believe unsuitable for the donation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Allogeneic γδT cell immunotherapy
Patients will receive 3 cycles of ex-vivo expanded allogeneic γδT cells treatments, at four-weeks' intervals, each cycle has 2 infusions.
Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
|
Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation.
The ex-vivo expanded γδT cells from donors will be adoptively transfused.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety evaluation: Incidence of Adverse events (AEs)
Time Frame: up to 48 weeks
|
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).
|
up to 48 weeks
|
Safety evaluation: Dose limited toxicity (DLTs)
Time Frame: up to 48 weeks
|
The incidence, characteristic and severity of DLTs will be recorded and assessed.
|
up to 48 weeks
|
Safety evaluation: Maximum-tolerated dose (MTD)
Time Frame: up to 48 weeks
|
MTD or clinical recommended dose will be recorded and evaluated.
|
up to 48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy evaluation: Quality of life by ECOG score
Time Frame: up to 48 weeks
|
The quality of life is assessed before and after the treatment by ECOG score .
|
up to 48 weeks
|
Efficacy evaluation: Tumor markers
Time Frame: up to 48 weeks
|
Tumor markers in peripheral blood will be tested and assessed (e. g.
AFP, AFP-L3).
|
up to 48 weeks
|
Efficacy evaluation: γδT cells in peripheral blood
Time Frame: up to 48 weeks
|
Number and phenotype of γδT cells in peripheral blood will be assessed by flow cytometry.
|
up to 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
August 15, 2020
Primary Completion (ANTICIPATED)
June 15, 2021
Study Completion (ANTICIPATED)
August 15, 2021
Study Registration Dates
First Submitted
August 17, 2020
First Submitted That Met QC Criteria
August 18, 2020
First Posted (ACTUAL)
August 19, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 19, 2020
Last Update Submitted That Met QC Criteria
August 18, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JDH-HCC-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on Ex-vivo expanded allogeneic γδT cells
-
Institute of Hematology & Blood Diseases HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...RecruitingNon-Hodgkin's Lymphoma (NHL) | Peripheral T Cell Lymphoma (PTCL)China
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Dartmouth-Hitchcock Medical CenterThe Leukemia and Lymphoma SocietyCompletedMyeloma | Transplant-eligible PatientsUnited States
-
King Edward Medical UniversityUnknownLipodystrophy | Craniofacial Microsomia | Mixed Connective Tissue Disease | Romberg's Disease
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Singapore General HospitalWhitehead Institute for Biomedical Research; Blood Services Group, Health Sciences...TerminatedLymphoma | Acute Leukemia | Myelodysplastic Syndrome | Myeloma | Chronic LeukemiaSingapore
-
Jeffrey BluestoneNational Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance...TerminatedAcute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoVUnited States
-
Wuhan Union Hospital, ChinaJinan University, ChinaUnknownAcute Myeloid LeukemiaChina
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Juvenile Diabetes...CompletedType 1 Diabetes MellitusUnited States